Sigma-Aldrich Expands RNAi Play with Genospectra Pact; Execs Reviewing List of Acquisition Candidates | GenomeWeb

Licensing certain technologies from privately held Genospectra, Sigma-Aldrich has further expanded its presence in the RNAi and cell-based assay fields.

As part of the alliance announced last week, the companies said they plan to develop new technology and products in the area of cell-based assays, and in particular aim to develop live-cell biosensor assay reagents that can provide real-time data on the location and activity of proteins in living cells.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.